This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort
Leukemia Open Access 15 July 2023
-
Biological and clinical implications of FGFR aberrations in paediatric and young adult cancers
Oncogene Open Access 02 May 2023
-
Progression to B acute lymphoblastic leukemia in 8p11 myeloproliferative syndrome with t(6;8)(q27;p12)
International Journal of Hematology Open Access 17 March 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Bain BJ, Gilliland DG, Horny H-P, Vardiman JW . Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1. In: Swerdlow S, Harris NL, Stein H, Jaffe ES, Theile J, Vardiman JW (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2008, 68–73.
Jackson CC, Medeiros LJ, Miranda RN . 8p11 myeloproliferative syndrome: a review. Hum Pathol 2010; 41: 461–476.
Demiroglu A, Steer EJ, Heath C, Taylor K, Bentley M, Allen SL et al. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood 2001; 98: 3778–3783.
Murati A, Arnoulet C, Lafage-Pochitaloff M, Adelaide J, Derre M, Slama B et al. Dual lympho-myeloproliferative disorder in a patient with t(8;22) with BCR-FGFR1 gene fusion. Int J Oncol 2005; 26: 1485–1492.
Haslam K, Langabeer SE, Kelly J, Coen N, O'Connell NM, Conneally E . Allogeneic hematopoietic stem cell transplantation for a BCR-FGFR1 myeloproliferative neoplasm presenting as acute lymphoblastic leukemia. Case Rep Hematol 2012; 2012: 620967.
Wakim JJ, Tirado CA, Chen W, Collins R . t(8;22)/BCR-FGFR1 myeloprolife-rative disorder presenting as B-acute lymphoblastic leukemia: report of a case treated with sorafenib and review of the literature. Leuk Res 2011; 35: e151–e153.
Morishige S, Oku E, Takata Y, Kimura Y, Arakawa F, Seki R et al. A case of 8p11 myeloproliferative syndrome with BCR-FGFR1 gene fusion presenting with trilineage acute leukemia/lymphoma, successfully treated by cord blood transplantation. Acta Haematol 2013; 129: 83–89.
Dolan M, Cioc A, Cross NC, Neglia JP, Tolar J . Favorable outcome of allogeneic hematopoietic cell transplantation for 8p11 myeloproliferative syndrome associated with BCR-FGFR1 gene fusion. Pediatr Blood Cancer 2012; 59: 194–196.
Chase A, Bryant C, Score J, Cross NC . Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome. Haematologica 2013; 98: 103–106.
Ren M, Qin H, Ren R, Cowell JK . Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities. Leukemia 2013; 27: 32–40.
Townsend W, Cross NC, Waghorn K, Somana K, Ramsay A, Thomson K et al. Clinical evidence for a graft-versus-tumour effect following allogenic HSCT fo t(8;13) atypical myeloproliferative disorder. Bone Marrow Transplant 2009; 44: 197–199.
Richebourg S, Theisen O, Plantier I, Parry A, Soenen-Cornu V, Lepelley P et al. Chronic myeloproliferative disorder with t(8;22)(p11;q11) can mime clonal cytogenetic evolution of authentic chronic myelogeneous leukemia. Genes Chromosomes Cancer 2008; 47: 915–918.
Fioretos T, Panagopoulos I, Lassen C, Swedin A, Billström R, Isaksson M et al. Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL. Genes Chromosomes Cancer 2001; 32: 302–310.
Chase A, Grand FH, Cross NC . Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood 2007; 110: 3729–3734.
Chen J, DeAngelo DJ, Kutok JL, Williams IR, Lee BH, Wadleigh M et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci USA 2004; 101: 14479–14484.
Acknowledgements
We express gratitude to Parveen Abidi and Larry Okumoto of the Stanford Hematology Division Tissue Bank for assistance with sample collection and processing, as well as Linda Gojenola from the Stanford Molecular Diagnostics Lab for assistance with DNA extraction. This work is supported by the Charles and Ann Johnson Foundation (JG).
Author Contributions
MSK, BCM, ASS, SA and JG provided care to the patient; RCJ, MDE and DAA performed hematopathologic evaluation of the case; CDB and AMC conducted FISH and cytogenetic studies; BL and JLZ performed all molecular diagnostic analyses. MSK, BL, BCM, RCJ, MDE, CDB, AMC, DAA, JLZ and JG analyzed the data. MSK and JG wrote the first draft of the manuscript. All the authors reviewed, provided input and approved the final draft of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Khodadoust, M., Luo, B., Medeiros, B. et al. Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia. Leukemia 30, 947–950 (2016). https://doi.org/10.1038/leu.2015.136
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2015.136
This article is cited by
-
Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort
Leukemia (2023)
-
Biological and clinical implications of FGFR aberrations in paediatric and young adult cancers
Oncogene (2023)
-
Progression to B acute lymphoblastic leukemia in 8p11 myeloproliferative syndrome with t(6;8)(q27;p12)
International Journal of Hematology (2023)
-
A truncated derivative of FGFR1 kinase cooperates with FLT3 and KIT to transform hematopoietic stem cells in syndromic and de novo AML
Molecular Cancer (2022)
-
Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT
Bone Marrow Transplantation (2022)